FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223443704> ?p ?o ?g. }

• W4223443704 abstract "Increasing cases of SARS-CoV-2 breakthrough infections from immunization with current spike protein-based COVID-19 vaccines highlight the need to develop alternative vaccines using different platforms and/or antigens. In this study, we expressed SARS-CoV-2 spike and nucleocapsid proteins based on a novel vaccinia virus (VACV) ACAM2000 platform (rACAM2000). In this platform, the vaccinia virus host range and immunoregulatory gene E3L was deleted to make the virus attenuated and to enhance innate immune responses, and another host range gene, K3L, was replaced with a poxvirus ortholog gene, taterapox virus 037 (TATV037), to make virus replication competent in both hamster and human cells. Following a single intramuscular immunization, the rACAM2000 coexpressing the spike and nucleocapsid proteins induced significantly improved protection against SARS-CoV-2 challenge in comparison to rACAM2000 expressing the individual proteins in a hamster model, as shown by reduced weight loss and shorter recovery time. The protection was associated with reduced viral loads, increased neutralizing antibody titer, and reduced neutrophil-to-lymphocyte ratio. Thus, our study demonstrates that rACAM2000 expressing a combination of the spike and nucleocapsid antigens is a promising COVID-19 vaccine candidate, and further studies will investigate if the rACAM2000 vaccine candidate can induce a long-lasting immunity against infection by SARS-CoV-2 variants of concern. IMPORTANCE Continuous emergence of SARS-CoV-2 variants which cause breakthrough infection from the immunity induced by current spike protein-based COVID-19 vaccines highlights the need for new generations of vaccines that will induce long-lasting immunity against a wide range of the variants. To this end, we investigated the protective efficacy of the recombinant COVID-19 vaccine candidates based on a novel VACV ACAM2000 platform, in which an immunoregulatory gene, E3L, was deleted and both the SARS-CoV-2 spike (S) and nucleocapsid (N) antigens were expressed. Thus, it is expected that the vaccine candidate we constructed should be more immunogenic and safer. In the initial study described in this work, we demonstrated that the vaccine candidate expressing both the S and N proteins is superior to the constructs expressing an individual protein (S or N) in protecting hamsters against SARS-CoV-2 challenge after a single-dose immunization, and further investigation against different SARS-CoV-2 variants will warrant future clinical evaluations." @default.
• W4223443704 created "2022-04-14" @default.
• W4223443704 creator A5002344673 @default.
• W4223443704 creator A5003718692 @default.
• W4223443704 creator A5005386190 @default.
• W4223443704 creator A5005578972 @default.
• W4223443704 creator A5007882592 @default.
• W4223443704 creator A5011718593 @default.
• W4223443704 creator A5014416326 @default.
• W4223443704 creator A5023827679 @default.
• W4223443704 creator A5026401972 @default.
• W4223443704 creator A5035647299 @default.
• W4223443704 creator A5049294928 @default.
• W4223443704 creator A5051175913 @default.
• W4223443704 creator A5053902677 @default.
• W4223443704 creator A5064631324 @default.
• W4223443704 creator A5068569099 @default.
• W4223443704 creator A5073748489 @default.
• W4223443704 creator A5074706957 @default.
• W4223443704 creator A5076588494 @default.
• W4223443704 creator A5083725943 @default.
• W4223443704 creator A5087866106 @default.
• W4223443704 date "2022-05-11" @default.
• W4223443704 modified "2023-09-27" @default.
• W4223443704 title "Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease" @default.
• W4223443704 cites W1975739500 @default.
• W4223443704 cites W2008402814 @default.
• W4223443704 cites W2019900764 @default.
• W4223443704 cites W2024268171 @default.
• W4223443704 cites W2033629536 @default.
• W4223443704 cites W2040865227 @default.
• W4223443704 cites W2042694122 @default.
• W4223443704 cites W2067968059 @default.
• W4223443704 cites W2071150424 @default.
• W4223443704 cites W2074590828 @default.
• W4223443704 cites W2117144423 @default.
• W4223443704 cites W2117564816 @default.
• W4223443704 cites W2143333377 @default.
• W4223443704 cites W2144804891 @default.
• W4223443704 cites W2146110475 @default.
• W4223443704 cites W2156310736 @default.
• W4223443704 cites W2166157172 @default.
• W4223443704 cites W2256756668 @default.
• W4223443704 cites W2409320959 @default.
• W4223443704 cites W2461565498 @default.
• W4223443704 cites W2504828590 @default.
• W4223443704 cites W2534183921 @default.
• W4223443704 cites W2750464792 @default.
• W4223443704 cites W2896334271 @default.
• W4223443704 cites W2997372608 @default.
• W4223443704 cites W3009859788 @default.
• W4223443704 cites W3024076634 @default.
• W4223443704 cites W3025063365 @default.
• W4223443704 cites W3035051352 @default.
• W4223443704 cites W3037085972 @default.
• W4223443704 cites W3042383115 @default.
• W4223443704 cites W3045724532 @default.
• W4223443704 cites W3046061621 @default.
• W4223443704 cites W3081741393 @default.
• W4223443704 cites W3088925205 @default.
• W4223443704 cites W3093367571 @default.
• W4223443704 cites W3094009122 @default.
• W4223443704 cites W3095956988 @default.
• W4223443704 cites W3106624201 @default.
• W4223443704 cites W3108193091 @default.
• W4223443704 cites W3108252585 @default.
• W4223443704 cites W3110244378 @default.
• W4223443704 cites W3113621889 @default.
• W4223443704 cites W3120929353 @default.
• W4223443704 cites W3127836986 @default.
• W4223443704 cites W3131688063 @default.
• W4223443704 cites W3131995220 @default.
• W4223443704 cites W3134749657 @default.
• W4223443704 cites W3138734145 @default.
• W4223443704 cites W3153636933 @default.
• W4223443704 cites W3154757366 @default.
• W4223443704 cites W3160306376 @default.
• W4223443704 cites W3164208781 @default.
• W4223443704 cites W3170389776 @default.
• W4223443704 cites W3174747632 @default.
• W4223443704 cites W3175747586 @default.
• W4223443704 cites W3175923549 @default.
• W4223443704 cites W3176225922 @default.
• W4223443704 cites W3186329587 @default.
• W4223443704 cites W3195795781 @default.
• W4223443704 cites W3198343668 @default.
• W4223443704 cites W3199631570 @default.
• W4223443704 cites W3200120416 @default.
• W4223443704 cites W3201177512 @default.
• W4223443704 cites W3202865001 @default.
• W4223443704 cites W3210126657 @default.
• W4223443704 cites W3210699700 @default.
• W4223443704 cites W3217636556 @default.
• W4223443704 cites W4205319177 @default.
• W4223443704 cites W4225296514 @default.
• W4223443704 cites W4226060119 @default.
• W4223443704 cites W4230889058 @default.
• W4223443704 doi "https://doi.org/10.1128/jvi.00389-22" @default.
• W4223443704 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35412347" @default.
• W4223443704 hasPublicationYear "2022" @default.

• next